minesapride

Minesapride (INNTooltip International Nonproprietary Name; developmental code name DSP-6952) is a serotonin 5-HT4 receptor agonist which was under development for the treatment of constipation and irritable bowel syndrome (IBS) but was never marketed. It is taken orally. The drug was under development by Dainippon Sumitomo Pharma. It reached phase 2 clinical trials prior to the discontinuation of its development. The drug showed inadequate effectiveness in phase 2 trials.